27631550|t|Neuroprotective Role of MicroRNA-22 in a 6-Hydroxydopamine - Induced Cell Model of Parkinson's Disease via Regulation of Its Target Gene TRPM7
27631550|a|Parkinson's disease (PD), the second most prevalent neurodegenerative disorder with only symptomatic treatment available, is characterized by a progressive loss of dopaminergic neurons in the midbrain. Ample evidence indicated that microRNAs (miRs) could regulate post-transcriptional gene expression and neuronal disease. In the present study, we have evaluated the effects and mechanism of miR-22 in PC12 pheochromocytoma cells treated with 6-hydroxydopamine (6-OHDA) to mimic PD. RT-PCR results showed that the expression of miR-22 is downregulated in 6-OHDA - treated PC12 cells, and the overexpression of miR-22 significantly promoted the survival and proliferation of 6-OHDA - induced PC12 cells, whereas miR-22 inhibitor reversed these effects. In addition, PC12 cells were treated with miR-22 mimics or inhibitor following 6-OHDA administration, which medicated ROS production and upregulation or downregulation of caspase-3 activity, respectively. A luciferase reporter assay revealed that transient receptor potential melastatin 7 (TRPM7) is a direct target gene of miR-22, and miR-22 overexpression markedly downregulated the level of TRPM7. Strikingly, further analysis showed that miR-22 mediated 6-OHDA - induced PC12 cell survival and proliferation by targeting TRPM7. Taken together, the present study showed that miR-22 overexpression exhibited neuroprotective and reversal effects on the 6-OHDA - induced PC12 cell growth and apoptosis by targeting TRPM7.
27631550	24	35	MicroRNA-22	T017	UMLS:C1537720
27631550	41	58	6-Hydroxydopamine	T103	UMLS:C0085196
27631550	69	73	Cell	T017	UMLS:C0007634
27631550	74	79	Model	T038	UMLS:C0684309
27631550	83	102	Parkinson's Disease	T038	UMLS:C0030567
27631550	107	117	Regulation	T038	UMLS:C0017263
27631550	132	136	Gene	T017	UMLS:C0017337
27631550	137	142	TRPM7	T017	UMLS:C1425224
27631550	143	162	Parkinson's disease	T038	UMLS:C0030567
27631550	164	166	PD	T038	UMLS:C0030567
27631550	185	194	prevalent	T082	UMLS:C0205391
27631550	195	221	neurodegenerative disorder	T038	UMLS:C0524851
27631550	244	253	treatment	T058	UMLS:C0087111
27631550	307	327	dopaminergic neurons	T017	UMLS:C1512035
27631550	335	343	midbrain	T017	UMLS:C0025462
27631550	375	384	microRNAs	T103	UMLS:C1101610
27631550	386	390	miRs	T103	UMLS:C1101610
27631550	398	427	regulate post-transcriptional	T038	UMLS:C1514248
27631550	428	443	gene expression	T038	UMLS:C0017262
27631550	448	464	neuronal disease	T038	UMLS:C0027765
27631550	481	486	study	T062	UMLS:C2603343
27631550	535	541	miR-22	T017	UMLS:C1537720
27631550	545	572	PC12 pheochromocytoma cells	T017	UMLS:C0085262
27631550	586	603	6-hydroxydopamine	T103	UMLS:C0085196
27631550	605	611	6-OHDA	T103	UMLS:C0085196
27631550	622	624	PD	T038	UMLS:C0030567
27631550	626	632	RT-PCR	T062	UMLS:C0599161
27631550	657	667	expression	T038	UMLS:C0017262
27631550	671	677	miR-22	T017	UMLS:C1537720
27631550	681	694	downregulated	T038	UMLS:C0013081
27631550	698	704	6-OHDA	T103	UMLS:C0085196
27631550	715	725	PC12 cells	T017	UMLS:C0085262
27631550	735	749	overexpression	T038	UMLS:C0017262
27631550	753	759	miR-22	T017	UMLS:C1537720
27631550	787	795	survival	T038	UMLS:C0007620
27631550	800	813	proliferation	T038	UMLS:C0596290
27631550	817	823	6-OHDA	T103	UMLS:C0085196
27631550	834	844	PC12 cells	T017	UMLS:C0085262
27631550	854	860	miR-22	T017	UMLS:C1537720
27631550	908	918	PC12 cells	T017	UMLS:C0085262
27631550	937	950	miR-22 mimics	T017	UMLS:C1537720
27631550	974	980	6-OHDA	T103	UMLS:C0085196
27631550	981	995	administration	T058	UMLS:C1533734
27631550	1013	1016	ROS	T103	UMLS:C0162772
27631550	1017	1027	production	T038	UMLS:C1148560
27631550	1032	1044	upregulation	T038	UMLS:C0041904
27631550	1048	1062	downregulation	T038	UMLS:C0013081
27631550	1066	1084	caspase-3 activity	T038	UMLS:C1150132
27631550	1102	1112	luciferase	T103	UMLS:C0024075
27631550	1122	1127	assay	T058	UMLS:C2717977
27631550	1142	1183	transient receptor potential melastatin 7	T017	UMLS:C1425224
27631550	1185	1190	TRPM7	T017	UMLS:C1425224
27631550	1211	1215	gene	T017	UMLS:C0017337
27631550	1219	1225	miR-22	T017	UMLS:C1537720
27631550	1231	1237	miR-22	T017	UMLS:C1537720
27631550	1238	1252	overexpression	T038	UMLS:C0017262
27631550	1262	1275	downregulated	T038	UMLS:C0013081
27631550	1289	1294	TRPM7	T017	UMLS:C1425224
27631550	1316	1324	analysis	T062	UMLS:C0936012
27631550	1337	1343	miR-22	T017	UMLS:C1537720
27631550	1353	1359	6-OHDA	T103	UMLS:C0085196
27631550	1370	1374	PC12	T017	UMLS:C0085262
27631550	1375	1388	cell survival	T038	UMLS:C0007620
27631550	1393	1406	proliferation	T038	UMLS:C0596290
27631550	1420	1425	TRPM7	T017	UMLS:C1425224
27631550	1455	1460	study	T062	UMLS:C2603343
27631550	1473	1479	miR-22	T017	UMLS:C1537720
27631550	1480	1494	overexpression	T038	UMLS:C0017262
27631550	1549	1555	6-OHDA	T103	UMLS:C0085196
27631550	1566	1570	PC12	T017	UMLS:C0085262
27631550	1571	1582	cell growth	T038	UMLS:C0007595
27631550	1587	1596	apoptosis	T038	UMLS:C0162638
27631550	1610	1615	TRPM7	T017	UMLS:C1425224